103 related articles for article (PubMed ID: 3732352)
1. Serum prolactin levels in women with breast cancer and their relationship to survival.
Wang DY; Hampson S; Kwa HG; Moore JW; Bulbrook RD; Fentiman IS; Hayward JL; King RJ; Millis RR; Rubens RD
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):487-92. PubMed ID: 3732352
[TBL] [Abstract][Full Text] [Related]
2. Serum prolactin levels and their relationship to survival in women with operable breast cancer.
Wang DY; Stepniewska KA; Allen DS; Fentiman IS; Bulbrook RD; Kwa HG; De Stavola BL; Reed MJ
J Clin Epidemiol; 1995 Jul; 48(7):959-68. PubMed ID: 7782804
[TBL] [Abstract][Full Text] [Related]
3. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.
Eliassen AH; Tworoger SS; Hankinson SE
Int J Cancer; 2007 Apr; 120(7):1536-41. PubMed ID: 17211859
[TBL] [Abstract][Full Text] [Related]
4. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
Faupel-Badger JM; Sherman ME; Garcia-Closas M; Gaudet MM; Falk RT; Andaya A; Pfeiffer RM; Yang XR; Lissowska J; Brinton LA; Peplonska B; Vonderhaar BK; Figueroa JD
Br J Cancer; 2010 Sep; 103(7):1097-102. PubMed ID: 20736944
[TBL] [Abstract][Full Text] [Related]
5. Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma. A preliminary report.
Olsson H; Ewers SB; Landin-Olsson M; Ranstam J
Acta Radiol Oncol; 1985; 24(1):57-9. PubMed ID: 2984903
[TBL] [Abstract][Full Text] [Related]
6. Plasma prolactin levels in patients with breast cancer.
Rose DP; Pruitt BT
Cancer; 1981 Dec; 48(12):2687-91. PubMed ID: 7306924
[TBL] [Abstract][Full Text] [Related]
7. Nyctohemeral changes in plasma prolactin levels and their relationship to breast cancer risk.
Wang DY; Sturzaker HE; Kwa HG; Verhofstad F; Hayward JL; Bulbrook RD
Int J Cancer; 1984 May; 33(5):629-32. PubMed ID: 6724738
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
Secreto G; Recchione C; Cavalleri A; Miraglia M; Dati V
Br J Cancer; 1983 Feb; 47(2):269-75. PubMed ID: 6824571
[TBL] [Abstract][Full Text] [Related]
9. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.
Tikk K; Sookthai D; Fortner RT; Johnson T; Rinaldi S; Romieu I; Tjønneland A; Olsen A; Overvad K; Clavel-Chapelon F; Baglietto L; Boeing H; Trichopoulou A; Lagiou P; Trichopoulos D; Masala G; Krogh V; Tumino R; Ricceri F; Mattiello A; Agudo A; Menéndez V; Sánchez MJ; Amiano P; Chirlaque MD; Barricarte A; Bueno-de-Mesquita HB; Monninkhof EM; Onland-Moret NC; Andresson A; Sund M; Weiderpass E; Khaw KT; Key TJ; Travis RC; Merritt MA; Riboli E; Dossus L; Kaaks R
Breast Cancer Res; 2015 Mar; 17(1):49. PubMed ID: 25887963
[TBL] [Abstract][Full Text] [Related]
10. Effects of radical mastectomy on prolactin blood levels in patients with breast cancer.
Barni S; Lissoni P; Paolorossi F; Crispino S; Rovelli F; Ferri L; Sormani A; D'Alonso U; Bugatti A; Nociti V
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1141-5. PubMed ID: 3653210
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum prolactin levels in advanced breast cancer.
Dowsett M; McGarrick GE; Harris AL; Coombes RC; Smith IE; Jeffcoate SL
Br J Cancer; 1983 Jun; 47(6):763-9. PubMed ID: 6860546
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of plasma prolactin levels and subsequent risk of breast cancer.
Kwa HG; Cleton F; Wang DY; Bulbrook RD; Bulstrode JC; Hayward JL; Millis RR; Cuzick J
Int J Cancer; 1981 Dec; 28(6):673-6. PubMed ID: 7333701
[TBL] [Abstract][Full Text] [Related]
13. Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer.
Wang DY; Knyba RE; Bulbrook RD; Millis RR; Hayward JL
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):25-31. PubMed ID: 6537913
[TBL] [Abstract][Full Text] [Related]
14. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
15. Plasma hormones in parous, nulliparous and postmenopausal Japanese women.
Hill P; Garbaczewski L; Kasumi K; Wynder EL
Cancer Lett; 1986 Nov; 33(2):131-6. PubMed ID: 3098404
[TBL] [Abstract][Full Text] [Related]
16. Reproductive history and prognosis in patients with operable breast cancer.
Korzeniowski S; Dyba T
Cancer; 1994 Sep; 74(5):1591-4. PubMed ID: 8062190
[TBL] [Abstract][Full Text] [Related]
17. The relationship between blood prolactin levels and risk of breast cancer in premenopausal women.
Wang DY; de Stavola BL; Bulbrook RD; Allen DS; Kwa HG; Verstraeten AA; Moore JW; Fentiman IS; Chaudary M; Hayward JL
Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1541-8. PubMed ID: 3678318
[TBL] [Abstract][Full Text] [Related]
18. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer.
Holtkamp W; Nagel GA; Wander HE; Rauschecker HF; von Heyden D
Int J Cancer; 1984 Sep; 34(3):323-8. PubMed ID: 6480153
[TBL] [Abstract][Full Text] [Related]
20. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women.
Wang DY; de Stavola BL; Bulbrook RD; Allen DS; Kwa HG; Verstraeten AA; Moore JW; Fentiman IS; Hayward JL; Gravelle IH
Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1225-31. PubMed ID: 3416905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
